Researchers found that ramucirumab and GSK1838705A (VEGFR2 and IGF1R inhibitors) increased the sensitivity of HCC cells to the combination of sorafenib and regorafenib at low concentrations (D''Alessandro et al., 2019). Here, IGF1R is linked to hepatocellular carcinoma.